Atlas Trials

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Clinical trial NCT03914300 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03914300
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRefractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaTall Cell Variant Thyroid Gland Papillary CarcinomaThyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma
Start date
2020-02-10
Primary completion
2024-10-17
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.